Saturday, August 27, 2016

Canaccord starts Merit Medical at buy

Canaccord starts Merit Medical at buy

July 19, 2016 by · Leave a Comment 

Tweet Canaccord Genuity initiated coverage of Merit Medical Systems (NASDAQ:MMSI) with a “buy” rating and $27 price target. The stock closed at $20.51 on Monday. Merit develops, manufactures, and commercializes a vast array of medical devices, targeting interventional and diagnostic procedures. “Gross margin improvement has been elusive over the past few years, but we believe […]

Canaccord upgrades Endologix to buy

Canaccord upgrades Endologix to buy

June 13, 2016 by · Leave a Comment 

Tweet Canaccord Genuity has upgraded Endologix (NASDAQ:ELGX) to “buy” from “hold” and raised its price target to $15.50 from $11.25. The stock closed at $12.68 on Friday. The company is developing Nellix as an endovascular aneurysm sealing (EVAS) system designed for the treatment of infrarenal abdominal aortic aneurysm (AAA) and is the only technology whose […]

Canaccord ups GenMark price target to $10.50

Canaccord ups GenMark price target to $10.50

June 9, 2016 by · Leave a Comment 

Tweet Canaccord Genuity has hiked its price target for GenMark Diagnostics (NASDAQ:GNMK) to $10.50 from $8. The stock closed at $9.27 on Wednesday. After the close yesterday, GNMK announced a major milestone, achieving CE Mark for both its ePlex instrument and ePlex Respiratory Pathogen Panel, which was three weeks ahead of its recent timeline by […]

Canaccord ups Spectranetics price target to $23.50

Canaccord ups Spectranetics price target to $23.50

April 29, 2016 by · Leave a Comment 

Tweet Canaccord Genuity has raised its price target on Spectranetics (NASDAQ:SPNC) to $23.50 from $20. The stock closed at $16.68 on Thursday. “Our bullish conviction heading into the Q1 print was validated by the strong quarterly performance that reflected a continuation of the positive trends from the second half of 2015,” writes analyst Jason Mills. […]

Canaccord starts CryoLife at buy

Canaccord starts CryoLife at buy

April 13, 2016 by · Leave a Comment 

Tweet Canaccord Genuity has launched coverage of CryoLife (NYSE:CRY) with a “buy” rating and $14 yearend price target. The stock closed at $11 on Tuesday. “We recommend small-cap GARP (growth at a reasonable price) investors build positions in CryoLife, which is actively building a cardiac surgery-focused company through targeted acquisitions that augment its strong, existing […]

Canaccord downgrades AngioDynamics to hold

Canaccord downgrades AngioDynamics to hold

April 5, 2016 by · Leave a Comment 

Tweet Canaccord Genuity has downgraded AngioDynamics (NASDAQ:ANGO) to “hold” from “buy” and reduced its price target to $13 from $14.50, following the abrupt departure of CEO, Joe DeVivo, “which we think will heighten investor concern near term, and increase uncertainty.” The stock closed at $12.14 on Monday. “What’s more, this change compounds myriad existing challenges […]

Canaccord starts Penumbra at buy

Canaccord starts Penumbra at buy

October 13, 2015 by · Leave a Comment 

Tweet Canaccord Genuity has initiated coverage of Penumbra (NYSE:PEN) with a “buy” rating and 12-month target price of $48, representing 20% upside potential over the next year. The stock closed at $39.14 on Monday. “There have been few times in our nearly two decades analyzing the med-tech industry that we have seen a small-cap company […]

Canaccord starts Vermillion at buy

Canaccord starts Vermillion at buy

August 11, 2015 by · Leave a Comment 

Tweet Canaccord Genuity has launched coverage of Vermillion (NASDAQ:VRML) with a “buy” rating and $4 price target. The stock closed at $1.89 on Monday. “We believe Vermillion is on track to expand into a high-value, diversified women’s health diagnostics company and is focused initially on ovarian cancer,” writes analyst Mark Massaro. “While we like the […]

Analysts raise price target for LeMaitre Vascular

Analysts raise price target for LeMaitre Vascular

July 29, 2015 by · Leave a Comment 

Tweet Canaccord Genuity and Roth Capital Partners have raised their price targets for LeMaitre Vascular (NASDAQ:LMAT) to $14.50 from $13, and to $14 from $11, respectively, after the company set another record sales quarter. The stock closed at $11.24 on Tuesday. “We continue to view LeMaitre as one of the most undervalued small-cap stocks in […]

Leerink, Canaccord launch coverage of HTG Molecular

Leerink, Canaccord launch coverage of HTG Molecular

June 2, 2015 by · Leave a Comment 

Tweet Analysts at Leerink Partners and Canaccord Genuity have initiated coverage of HTG Molecular Diagnostics (NASDAQ:HTGM) with “outperform” and “buy” ratings, respectively, and price targets of $18 and $17, respectively. The stock closed at $13.91 on Monday. “We believe in the company’s strong and deep management team and strong early relationships with big pharma, biotech, […]

Next Page »

Email Newsletters with Constant Contact
Google+